Nicholas A Larsen

age ~51

from Pawtucket, RI

Get Report

Also known as:

Connected to:

Nicholas Larsen Phones & Addresses

Piperazine Compounds For Inhibiting Cps1
view source
US Patent:

20230026271, Jan 26, 2023
Filed:

Nov 20, 2020
Appl. No.:

17/778635
Inventors:

- Bunkyo-ku, Tokyo, JP
David BOLDUC - Milton MA, US
Nicholas LARSEN - Needham MA, US
Andrew S. COOK - Stow MA, US
Kiyoyuki OMOTO - Bedford MA, US
Assignee:

Eisai R&D Management Co., Ltd. - Bunkyo-ku, Tokyo
International Classification:

C07D 241/04
C07D 403/06
C07D 405/06
C07D 413/06
Abstract:

We provide compounds that may be useful as CPS1 inhibitors. These compounds may be useful, for example, in the treatment of cancer.

Tetrasubstituted Alkene Compounds And Their Use For The Treatment Of Breast Cancer
view source
US Patent:

20200255415, Aug 13, 2020
Filed:

Nov 22, 2017
Appl. No.:

16/349479
Inventors:

- Tokyo, JP
Ming-Hong Hao - Quincy MA, US
Manav Korpal - Winchester MA, US
Vijay Kumar Nyavanandi - Andhra Pradesh, IN
Xiaoling Puyang - Cambridge MA, US
Susanta Samajdar - Karnataka, IN
Peter Gerard Smith - Arlington MA, US
John Wang - Andover MA, US
Guo Zhu Zheng - Lexington MA, US
Ping Zhu - Acton MA, US
Lorna Helen Mitchell - Cambridge MA, US
Nicholas Larsen - Needham MA, US
Nathalie Rioux - Woburn MA, US
Sudeep Prajapati - Somerville MA, US
Dominic Reynolds - Stoneham MA, US
Morgan O'Shea - Waltham MA, US
Thiwanka Samarakoon - Westwood MA, US
Assignee:

Eisai R&D Management Co., Ltd. - Tokyo
International Classification:

C07D 413/14
A61P 35/00
C07D 231/56
C07D 401/10
C07D 401/14
C07D 401/12
C07D 413/12
C07D 403/10
Abstract:

Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.

Tetrasubstituted Alkene Compounds And Their Use
view source
US Patent:

20190337921, Nov 7, 2019
Filed:

Nov 22, 2017
Appl. No.:

16/349508
Inventors:

- Tokyo, JP
Ming-Hong Hao - Quincy MA, US
Manav Korpal - Winchester MA, US
Vijay Kumar Nyavanandi - Andhra Pradesh, IN
Xiaoling Puyang - Cambridge MA, US
Susanta Samajdar - Karnataka, IN
Peter Gerard Smith - Arlington MA, US
John Wang - Andover MA, US
Guo Zhu Zheng - Lexington MA, US
Ping Zhu - Acton MA, US
Lorna Helen Mitchell - Cambridge MA, US
Nicholas Larsen - Needham MA, US
Nathalie Rioux - Woburn MA, US
Assignee:

Eisai R&D Management Co., Ltd. - Tokyo
International Classification:

C07D 401/06
C07D 209/08
C07D 401/14
A61P 35/00
Abstract:

Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.

Tetrasubstituted Alkene Compounds And Their Use
view source
US Patent:

20180141913, May 24, 2018
Filed:

Nov 22, 2017
Appl. No.:

15/821367
Inventors:

- Tokyo, JP
Ming-Hong HAO - Quincy MA, US
Manav KORPAL - Winchester MA, US
Vijay Kumar NYAVANANDI - Hyderabad, IN
Xiaoling PUYANG - Cambridge MA, US
Susanta SAMAJDAR - Bangalore, IN
Peter Gerard SMITH - Arlington MA, US
John WANG - Andover MA, US
Guo Zhu ZHENG - Lexington MA, US
Ping ZHU - Boxborough MA, US
Lorna Helen MITCHELL - Cambridge MA, US
Nicholas LARSEN - Needham MA, US
Nathalie RIOUX - Woburn MA, US
Sudeep PRAJAPATI - Somerville MA, US
Dominic REYNOLDS - Stoneham MA, US
Morgan O'SHEA - Waltham MA, US
Thiwanka SAMARAKOON - Westwood MA, US
Assignee:

EISAI R & D MANAGEMENT CO., LTD. - Tokyo
International Classification:

C07D 231/56
C07D 401/14
C07D 401/10
C07D 413/12
C07D 413/14
A61P 35/00
Abstract:

Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.